Advertisement

Topics

Sangamo 1st to Show Human Gene-Editing Results. Investors Say ‘Meh.’

15:35 EDT 5 Sep 2018 | Xconomy

The first results from a landmark study of gene editing in humans came out today, and investors panned the study’s sponsor, Sangamo Therapeutics. The very early returns—from only four patients still in the midst of the study—are from a gene-manipulation technology called zinc finger nucleases, which is wholly owned by Richmond, CA-based Sangamo (NASDAQ: SGMO). […]

Original Article: Sangamo 1st to Show Human Gene-Editing Results. Investors Say ‘Meh.’

NEXT ARTICLE

More From BioPortfolio on "Sangamo 1st to Show Human Gene-Editing Results. Investors Say ‘Meh.’"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...